Brief: Vaccinex Presents Updated Interim Data From A Phase 1B/2 Study Of Pepinemab (Vx15/2503) In Combination With Avelumab (Bavencio) In Non-Small Cell Lung Cancer
27/09/2019 12:38
Sept 27 (Reuters) - Vaccinex Inc VCNX.O :
* VACCINEX PRESENTS UPDATED INTERIM DATA FROM A PHASE 1B/2
STUDY
OF PEPINEMAB (VX15/2503) IN COMBINATION WITH AVELUMAB
(BAVENCIO®) IN NON-SMALL CELL LUNG CANCER IN PODIUM AND POSTER
PRESENTATIONS AT THE FIFTH INTERNATIONAL CANCER LMMUNOTHERAPY
CONFERENCE IN PARIS, FRANCE
* VACCINEX- 59% OF PATIENTS WHOSE TUMORS PROGRESSED DURING
TREATMENT WITH CHECKPOINT INHIBITORS SEEMED TO BENEFIT FROM
SWITCHING TO PEPINEMAB + AVELUMAB
* VACCINEX INC - AMONG 17 RESPONDERS, TWO HAD PARTIAL
RESPONSES
WITH 49% AND 37% TUMOR REDUCTIONS ON COMBINATION THERAPY AFTER
FAILURE OF PEMBROLIZUMAB
* VACCINEX INC - NO CONCERNING SAFETY SIGNALS WITH
COMBINATION OF
PEPINEMAB AND AVELUMAB HAVE BEEN IDENTIFIED BY INVESTIGATORS TO
DATE
* VACCINEX INC - THERE HAVE BEEN NO DROPOUTS OR
DISCONTINUATIONS
DUE TO TOXICITY.
Source text for Eikon: ID:nGNX5tpd9n
Further company coverage: VCNX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vaccinex
See all newsBrief: Vaccinex Reports Third Quarter 2024 Financial Results And Provides Corporate Update
Brief: Vaccinex Says On Oct 7, Got Letter From The Nasdaq Listing Staff Stating That Co Had Not Regained Compliance With The Equity Standard
Brief: VaccinexExercise Of Warrants For $6.2 Million In Gross Proceeds
Brief: Vaccinex Provides Update On New Findings For Signal-Ad Phase 1B/2 Trial Of Pepinemab In Alzheimer’S Disease
Brief: Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease